INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 30, 2025, Summit issued a press release “announc[ing] topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab[.]”  Although patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die than patients who received chemo alone, the drug failed to make a statistically significant difference in overall survival, a metric that measures how long patients live before dying of any cause. 

On this news, Summit’s stock price fell $7.99 per share, or 30.5%, to close at $18.22 per share on May 30, 2025. 

Then, on September 7, 2025, Summit announced additional data from the trial, in which ivonescimab produced weaker results in patients from North America and Europe than in those from Europe. 

On this news, Summit’s stock price fell $6.54 per share, or 25.15%, to close at $19.45 per share on September 8, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Agios and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 4, 2025, Agios issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025.”  

On news of the delayed review, Agios’s stock price fell $4.48 per share, or 11.03%, to close at $36.13 per share on September 4, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Cybin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

We are investigating Cybin Inc. (CYBN) (“Cybin” or the “Company”) for potential violations of the federal securities laws.  On September 2, 2025, Cybin issued a press release “annnounc[ing] that, effective September 2, 2025, Doug Drysdale will step down as the Company’s Chief Executive Officer.” 

On this news, Cybin’s stock price fell $1.24 per share, or 16.58%, to close at $6.24 per share on September 2, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skillz Inc.– SKLZ

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Skillz Inc. (“Skillz” or the “Company”) (NYSE: SKLZ).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Skillz and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 2, 2025, Skillz disclosed in a filing with the U.S. Securities and Exchange Commission that Tether Studios and its affiliate Tether Games (together, “Tether”) plan to terminate all agreements with Skillz, effective September 1, 2025.  Under the agreements, Skillz has licensed its software to Tether for use in monetizing Tether’s games.  In return, both companies share the revenue from user entry fees.  After receiving the notice, Skillz filed a lawsuit on September 1, 2025, seeking to block Tether’s termination of their agreements.  Skillz is also disputing Tether’s reasons for ending the deal. 

On this news, Skillz’s stock price fell $1.50 per share, or 17.22%, to close at $7.21 per share on September 3, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EHang Holdings Limited - EH

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: EH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether EHang and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 26, 2025, EHang reduced its 2025 revenue projection to 500 million yuan from 900 million yuan, prompting Morgan Stanley to lower its forecasts for the Company. 

On this news, EHang’s American Depositary Receipt (“ADR”) price fell $1.34 per ADR, or 7.53%, to close at $16.45 per ADR on August 26, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Axogen, Inc. (“Axogen” or the “Company”) (NASDAQ: AXGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Axogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 25, 2025, Axogen issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025.” 

On this news, Axogen’s stock price fell $1.47 per share, or 9.04%, to close at $14.79 per share on August 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Valneva and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On February 25, 2025, the U.S. Centers for Disease Control and Prevention (“CDC”) posted a notice on its website announcing that “CDC is currently investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ [Valneva’s chikungunya virus vaccine] among people 65 years of age and older.” 

Following the CDC’s announcement and subsequent reporting by media outlets, Valneva’s American Depositary Receipt (“ADR”) price fell $1.06 per ADR, or 13.57%, over the following four trading sessions, to close at $6.75 per ADR on February 28, 2025. 

Then, on August 22, 2025, the U.S. Food and Drug Administration announced that it had suspended the marketing application for IXCHIQ due to safety concerns. 

On this news, Valneva’s ADR price fell $2.21 per ADR, or 18.99%, to close at $9.43 per ADR on August 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Coty Inc. – COTY

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Coty Inc. (“Coty” or the “Company”) (NYSE: COTY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Coty and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 20, 2025, Coty issued a press release reporting its financial results its full fiscal year 2025 and fourth quarter.  Among other items, Coty reported an unexpected loss and provided disappointing guidance.  Discussing the results on an earnings call, Coty’s Chief Financial Officer said that “[t]he challenges of fiscal year 2025 coincided with moderating profit in the broader beauty market,” attributing sluggish sales to factors ranging from value-seeking behavior, innovation fatigue by consumers, and anti-theft and immigration policy changes. 

On this news, Coty’s stock price fell $1.05 per share, or 21.6%, to close at $3.81 per share on August 21, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 15, 2025, Scorpion Capital (“Scorpion”) published a report that described Soleno’s only product, Vykat XR, as overpriced and potentially unsafe for children. 

Following publication of the Scorpion report, Soleno’s stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Roblox Corporation – RBLX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Roblox Corporation (“Roblox” or the “Company”) (NYSE: RBLX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Roblox and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 14, 2025, Louisiana Attorney General Liz Murrill filed a lawsuit against Roblox, alleging that the lack of controls on the Company’s online gaming platform “allow[s] child predators to pose as children and for children to bypass any age requirement”, thereby creating an unchecked forum for sexual predators to connect with children and facilitating the sharing of sexually explicit material. 

As media outlets reported on the lawsuit, Roblox’s stock price fell $7.94 per share, or 6.34%, to close at $117.34 per share on August 15, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Align Technology, Inc. – ALGN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Align Technology, Inc. (“Align” or the “Company”) (NASDAQ: ALGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether Align and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On July 30, 2025, Align issued a press release announcing its financial results for the second quarter of 2025.  Among other items, Align reported total revenues of approximately $1.01 billion, missing both consensus estimates and the Company’s own guidance.  Align also lowered its third-quarter revenue guidance and full-year growth expectations, citing “the potential continued economic uncertainty and spending hesitancy that impacted demand for our clear aligners and new iTero scanner systems in the second quarter.” 

On this news, Align’s stock price fell $74.56 per share, or 36.63%, to close at $129.01 per share on July 31, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes. 

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innovative Solutions and Support, Inc. - ISSC

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Innovative Solutions and Support, Inc. (“IS&S” or the “Company”) (NASDAQ: ISSC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

The investigation concerns whether IS&S and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 14, 2025, IS&S issued a press release announcing its financial results for its fiscal third quarter of 2025.  Therein, the Company’s Chief Executive Officer Shahram Askarpour advised, among other things, that a “pull-forward of F-16 production into the current quarter . . . will impact revenue over the next two quarters[.]” 

On this news, IS&S’s stock price fell $6.22 per share, or 31.53%, to close at $13.51 per share on August 14, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Broadwind, Inc. - BWEN

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of Broadwind, Inc. (“Broadwind” or the “Company”) (NASDAQ: BWEN).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Broadwind and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On August 12, 2025, Broadwind issued a press release announcing its financial results for the second quarter of 2025.  Among other results, the Company reported a GAAP loss per share of $0.04 for the quarter, missing consensus estimates by $0.05.  The Company also suspended its previously issued full-year 2025 financial guidance as a result of a definitive agreement that it had entered into to sell its industrial fabrication operations in Manitowoc, Wisconsin.

On this news, Broadwind’s stock price fell $0.36 per share, or 14.46%, to close at $2.13 per share on August 12, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stitch Fix, Inc. - SFIX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Stitch Fix, Inc. (“Stitch Fix” or the “Company”) (NASDAQ: SFIX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Stitch Fix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 24, 2025, Stitch Fix issued a press release announcing its financial results for the fourth quarter and full fiscal year 2025, ended August 2, 2025.  Among other items, Stitch Fix reported a fifteenth consecutive quarter of subscriber loss, along with weakening gross margin rates and advertising spending that is reaching 10% of revenue.  During an accompanying earnings call, the Company’s Chief Financial Officer warned that Stitch Fix is entering the holiday season with a “challenging macro environment,” and a narrower profit margin due to higher transportation costs and “ongoing strategic investments in our client experience and assortment.” 

On this news, Stitch Fix’s stock price fell $0.93 per share, or 16.49%, to close at $4.71 per share on September 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CarMax, Inc. - KMX

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 25, 2025, CarMax issued a press release reporting its financial results for the second quarter of its 2026 fiscal year.  CarMax reported earnings per share (“EPS”) of only $0.64 on $6.6 billion in sales, falling well short of consensus estimates of EPS of $1.03 on $7 billion in sales.  CarMax’s Chief Executive Officer described the quarter as “challenging” and said that the Company would cut selling, general and administrative spending by $150 million over the next 18 months. 

On this news, CarMax’s stock price fell $11.5 per share, or 20.07%, to close at $45.60 per share on September 25, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reddit, Inc. - RDDT

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Reddit, Inc. (“Reddit” or the “Company”) (NYSE: RDDT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Reddit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 1, 2025, RBC Capital Analyst Brad Erickson published a note, stating, in part, that “data showing declining DAU’s [daily active users] on a [trailing 30-day average] is making the rounds on social media this morning and weighing on [Reddit’s] stock, along with other third-parties flagging that Reddit’s citation share on ChatGPT has gone down significantly recently.” 

On this news, Reddit’s stock price fell $27.39 per share, or 11.91%, to close at $202.60 per share on October 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Trinseo PLC - TSE

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Trinseo PLC (“Trinseo” or the “Company”) (NYSE: TSE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Trinseo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 6, 2025, Trinseo announced that it is indefinitely suspending its quarterly dividend and permanently closing its methyl methacrylate production operations in Rho, Italy, and its acetone cyanohydrin production operations in Porto Marghera, Italy.  Trinseo said that its actions are aimed at further optimizing its operations, enhancing cash flow generation and strengthening long-term profitability. 

On this news, Trinseo’s stock price fell $0.29 per share, or 12.21%, to close at $2.05 per share on October 7, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Braskem S.A. - BAK

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Braskem S.A. (“Braskem” or the “Company”) (NYSE: BAK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Braskem and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 26, 2025, Braskem announced “that it has retained financial and legal advisors to support the Company in preparing a diagnosis of economic-financial alternatives to optimize its capital structure.” 

On this news, Braskem’s American Depositary Receipt (“ADR”) price fell $0.45 per ADR, or 14.71%, to close at $2.61 per ADR on September 26, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYE

NEW YORK, Pomerantz LLP is investigating claims on behalf of investors of  Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Skye and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 6, 2025, Skye issued a press release “announc[ing] the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody.”  The press release disclosed that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.” 

On this news, Skye’s stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Marex Group Plc of Class Action Lawsuit and Upcoming Deadlines - MRX

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Marex Group Plc (“Marex” or the “Company”) (NASDAQ: MRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Marex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 8, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Marex securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On August 5, 2025, NINGI Research published a report entitled “Marex Group plc: A Financial House of Cards.”  In announcing the report, NINGI Research stated that, in its opinion, “Marex has engaged in a multi-year accounting scheme involving a web of opaque off-balance-sheet entities, fictitious intercompany transactions, and misleading disclosures to conceal significant losses, inflate profits, and mask its true risk exposure. We have uncovered evidence suggesting Marex is a financial house of cards, with a balance sheet riddled with holes and financials that we believe are unreliable.” 

On this news, Marex’s stock price fell $2.33 per share, or 6.19%, to close at $35.31 per share on August 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.